Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

Allergen immunotherapy with omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab has shown promising outcomes in preventing asthma exacerbations. Real-world studies ...

Targeted drugs, such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab, have shown remarkable efficacy. Sustained improvements in pulmonary function, reduced exacerbations ...